Unknown

Dataset Information

0

Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis.


ABSTRACT: Clinical trials where cancer patients were treated with protease inhibitors have suggested that the serine protease, prostasin, may act as a tumour suppressor. Prostasin is proteolytically activated by the serine protease, matriptase, which has a very high oncogenic potential. Prostasin is inhibited by protease nexin-1 (PN-1) and the two isoforms encoded by the mRNA splice variants of hepatocyte growth factor activator inhibitor-1 (HAI-1), HAI-1A, and HAI-1B.Using quantitative RT-PCR, we have determined the mRNA levels for prostasin and PN-1 in colorectal cancer tissue (n = 116), severe dysplasia (n = 13), mild/moderate dysplasia (n = 93), and in normal tissue from the same individuals. In addition, corresponding tissues were examined from healthy volunteers (n = 23). A part of the cohort was further analysed for the mRNA levels of the two variants of HAI-1, here denoted HAI-1A and HAI-1B. mRNA levels were normalised to beta-actin. Immunohistochemical analysis of prostasin and HAI-1 was performed on normal and cancer tissue.The mRNA level of prostasin was slightly but significantly decreased in both mild/moderate dysplasia (p < 0.001) and severe dysplasia (p < 0.01) and in carcinomas (p < 0.05) compared to normal tissue from the same individual. The mRNA level of PN-1 was more that two-fold elevated in colorectal cancer tissue as compared to healthy individuals (p < 0.001) and elevated in both mild/moderate dysplasia (p < 0.01), severe dysplasia (p < 0.05) and in colorectal cancer tissue (p < 0.001) as compared to normal tissue from the same individual. The mRNA levels of HAI-1A and HAI-1B mRNAs showed the same patterns of expression. Immunohistochemistry showed that prostasin is located mainly on the apical plasma membrane in normal colorectal tissue. A large variation was found in the degree of polarization of prostasin in colorectal cancer tissue.These results show that the mRNA level of PN-1 is significantly elevated in colorectal cancer tissue. Future studies are required to clarify whether down-regulation of prostasin activity via up regulation of PN-1 is causing the malignant progression or if it is a consequence of it.

SUBMITTER: Selzer-Plon J 

PROVIDER: S-EPMC2717118 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis.

Selzer-Plon Joanna J   Bornholdt Jette J   Friis Stine S   Bisgaard Hanne C HC   Lothe Inger Mb IM   Tveit Kjell M KM   Kure Elin H EH   Vogel Ulla U   Vogel Lotte K LK  

BMC cancer 20090625


<h4>Background</h4>Clinical trials where cancer patients were treated with protease inhibitors have suggested that the serine protease, prostasin, may act as a tumour suppressor. Prostasin is proteolytically activated by the serine protease, matriptase, which has a very high oncogenic potential. Prostasin is inhibited by protease nexin-1 (PN-1) and the two isoforms encoded by the mRNA splice variants of hepatocyte growth factor activator inhibitor-1 (HAI-1), HAI-1A, and HAI-1B.<h4>Methods</h4>Us  ...[more]

Similar Datasets

| S-EPMC2684122 | biostudies-literature
| S-EPMC8273379 | biostudies-literature
| S-EPMC6037773 | biostudies-literature
| S-EPMC1184062 | biostudies-literature
| S-EPMC137549 | biostudies-literature
2020-04-13 | GSE130012 | GEO
| PRJNA533611 | ENA
| S-EPMC3747088 | biostudies-literature
| S-EPMC6856719 | biostudies-literature
| S-EPMC2376921 | biostudies-other